

Cover Story
It's not just the absence of a randomized trial that prompted the FDA Oncologic Drugs Advisory Committee to recommend against an accelerated approval of the Karyopharm Therapeutics Inc. drug selinexor for late-stage multiple myeloma.
Clinical Roundup


Drugs & Targets
Trending Stories
- Narjust Duma named associate director of the Cancer Care Equity Program at DFCI, Harvard Medical School
- Robert Stone: City of Hope aims to transform cancer care nationally through new models, partnerships
- Biden commits to creating “ARPA-H” research body in visit to Ohio State
- Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44
- The Cancer Letter gets a new website
- Abecma receives FDA approval for multiple myeloma